MONTEFIORE MEDICAL CENTER
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.montefiore.org
Clinical Trials
388
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (334 trials with phase data)• Click on a phase to view related trials
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
- Conditions
- Low Back Pain, Chronic
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT07214844
- Locations
- 🇺🇸
Montefiore Multidisciplinary Pain Program, The Bronx, New York, United States
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
- Conditions
- Opioid Use Disorder
- Interventions
- Other: Placebo DronabinolOther: Placebo Epidiolex
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT07148206
- Locations
- 🇺🇸
Montefiore Health System (Montefiore) Buprenorphine Treatment Network, The Bronx, New York, United States
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT07146230
- Locations
- 🇺🇸
Montefiore Medical Center, The Bronx, New York, United States
Virtual Intelligence for Transformative Lifestyle Solutions in Pain
- Conditions
- Chronic Pain
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT07124598
- Locations
- 🇺🇸
Montefiore Multidisciplinary Pain Medicine Program (MMPP) at Montefiore Einstein Hutchinson Campus, The Bronx, New York, United States
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer
- Conditions
- Peripheral NeuropathyBreast Cancer
- Interventions
- Drug: PlaceboDrug: Desloratodine
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 116
- Registration Number
- NCT07109817
- Locations
- 🇺🇸
Montefiore Medical Center, The Bronx, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 78
- Next
News
New PPAR Agonists Expand Treatment Landscape for Primary Biliary Cholangitis
Ursodeoxycholic acid (UDCA), while groundbreaking, leaves up to 40% of Primary Biliary Cholangitis patients with inadequate response, highlighting the need for additional treatment options.
Hoth Therapeutics Expands HT-001 Phase 2a Trial for EGFRi-Induced Skin Toxicities
Hoth Therapeutics has received IRB approval from Montefiore Medical Center and Dana-Farber Cancer Institute for its Phase 2a trial of HT-001.
Real-World Teclistamab Data Shows Comparable Efficacy to Clinical Trials Despite Higher Toxicity Rates in Multiple Myeloma
A multicenter real-world study of 110 patients treated with teclistamab demonstrated a 62% overall response rate and 51% very good partial response rate, comparable to the pivotal MajesTEC-1 trial despite treating a more heavily pretreated population.